8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4 Linagliptin Intermediate Purity ≥99.0% (HPLC) Factory

Short Description:

Name: 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine

CAS: 666816-98-4

Purity: ≥99.0% (HPLC)

Appearance: White to Off-White Powder

Intermediate for Linagliptin (CAS: 668270-12-0) for the treatment of adults with type 2 diabetes mellitus.

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Linagliptin and Related Intermediates:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermediate CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4
2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6
(R)-3-(Boc-Amino)piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0

Chemical Properties:

Chemical Name	8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine
Synonyms	8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione; Linagliptin Intermediate C
CAS Number	666816-98-4
CAT Number	RF-PI497
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C10H9BrN4O2
Molecular Weight	297.11
Melting Point	285℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Water (K.F)	≤0.50%
Residue on Ignition	≤0.50%
Purity/Analysis Method	≥99.0% (HPLC)
Max Single Impurity	≤0.50%
Residual Solvents
Ethanol	≤5000ppm
DMF	≤3000ppm
Test Standard	Enterprise Standard
Usage	Intermediate for Linagliptin (CAS: 668270-12-0)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine (CAS: 666816-98-4) is an intermediate for Linagliptin (CAS: 668270-12-0). Linagliptin is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus. Linagliptin was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise.